Peter Maslak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peter Maslak has a total of 394 co-authors. Here are the top co-authors by number of shared publications:
- Santosha A. Vardhana
Memorial Sloan Kettering Cancer Center, New York, NY
20 shared publications Alexander Solovyov
19 shared publicationsBenjamin Greenbaum
19 shared publications- Christina Y. Lee
Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY
19 shared publications David Hoyos
19 shared publicationsMelanie Douglas
19 shared publications
Latest Publications
- Open Access
- 25 May 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (8) , 808.e1-808.e13
Outcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors
- 25 May 2024
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 30 (8) , 808.e1-808.e13
Open AccessOutcomes of Human Leukocyte Antigen-Matched Related Donor and Haploidentical Allogeneic Hematopoietic Cell Transplantation Recipients by Immune Profiles of Recipients and Donors
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Figure from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Figure from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Supplementary Table from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Coronavirus disease 2019 (COVID-19) infection results in both acute mortality and persistent and/or recurrent disease in patients with hematologic malignancies, but the drivers of persistent infection in this population are unknown. We found that B-cell lymphomas were at particularly high risk for persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity. Further analysis of these patients identified discrete risk factors for initial disease severity compared with disease chronicity. Active therapy and diminished T-cell counts were drivers of acute mortality in COVID-19–infected patients with lymphoma. Conversely, B cell–depleting therapy was the primary driver of rehospitalization for COVID-19. In patients with persistent SARS-CoV-2 positivity, we observed high levels of viral entropy consistent with intrahost viral evolution, particularly in patients with impaired CD8+ T-cell immunity. These results suggest that persistent COVID-19 infection is likely to remain a risk in patients with impaired adaptive immunity and that additional therapeutic strategies are needed to enable viral clearance in this high-risk population.Significance:We describe the largest cohort of persistent symptomatic COVID-19 infection in patients with lymphoid malignancies and identify B-cell depletion as the key immunologic driver of persistent infection. Furthermore, we demonstrate ongoing intrahost viral evolution in patients with persistent COVID-19 infection, particularly in patients with impaired CD8+ T-cell immunity.This article is highlighted in the In This Issue feature, p. 1
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies
Coronavirus disease 2019 (COVID-19) infection results in both acute mortality and persistent and/or recurrent disease in patients with hematologic malignancies, but the drivers of persistent infection in this population are unknown. We found that B-cell lymphomas were at particularly high risk for persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positivity. Further analysis of these patients identified discrete risk factors for initial disease severity compared with disease chronicity. Active therapy and diminished T-cell counts were drivers of acute mortality in COVID-19–infected patients with lymphoma. Conversely, B cell–depleting therapy was the primary driver of rehospitalization for COVID-19. In patients with persistent SARS-CoV-2 positivity, we observed high levels of viral entropy consistent with intrahost viral evolution, particularly in patients with impaired CD8+ T-cell immunity. These results suggest that persistent COVID-19 infection is likely to remain a risk in patients with impaired adaptive immunity and that additional therapeutic strategies are needed to enable viral clearance in this high-risk population.Significance:We describe the largest cohort of persistent symptomatic COVID-19 infection in patients with lymphoid malignancies and identify B-cell depletion as the key immunologic driver of persistent infection. Furthermore, we demonstrate ongoing intrahost viral evolution in patients with persistent COVID-19 infection, particularly in patients with impaired CD8+ T-cell immunity.This article is highlighted in the In This Issue feature, p. 1